T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| 1 |
Schlumberger
SLB
|
+$2.5B |
| 2 |
Kenvue
KVUE
|
+$1.3B |
| 3 |
Halliburton
HAL
|
+$1.16B |
| 4 |
Charles Schwab
SCHW
|
+$836M |
| 5 |
Boeing
BA
|
+$832M |
Top Sells
| 1 |
Microsoft
MSFT
|
+$2.52B |
| 2 |
Apple
AAPL
|
+$1.77B |
| 3 |
Advanced Micro Devices
AMD
|
+$1.57B |
| 4 |
Johnson & Johnson
JNJ
|
+$1.47B |
| 5 |
Intuit
INTU
|
+$1.14B |
Sector Composition
| 1 | Technology | 29.85% |
| 2 | Healthcare | 16.84% |
| 3 | Financials | 10.89% |
| 4 | Consumer Discretionary | 10.77% |
| 5 | Communication Services | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
926
Immatics
IMTX
$706M
| $18.7M | ﹤0.01% |
1,614,535
+893,328
| +124% | +$10.3M |
|
927
Nurix Therapeutics
NRIX
$684M
| $18.7M | ﹤0.01% |
2,377,978
-1,895
| -0.1% | -$14.9K |
|
928
Ormat Technologies
ORA
$5.51B
| $18.7M | ﹤0.01% |
266,730
+2,083
| +0.8% | +$146K |
|
929
Graco
GGG
$14.1B
| $18.6M | ﹤0.01% |
255,526
-46,924
| -16% | -$3.42M |
|
930
Monte Rosa Therapeutics
GLUE
$296M
| $18.5M | ﹤0.01% |
3,870,547
-25,951
| -0.7% | -$124K |
|
931
Herc Holdings
HRI
$4.43B
| $18.5M | ﹤0.01% |
155,521
-8,176
| -5% | -$972K |
|
932
Palantir
PLTR
$396B
| $18.5M | ﹤0.01% |
1,153,861
+29,319
| +3% | +$469K |
|
933
Carnival Corp
CCL
$42.5B
| $18.4M | ﹤0.01% |
1,340,467
+5,024
| +0.4% | +$68.9K |
|
|
BCPC
934
Balchem Corporation
BCPC
$5.05B
| $18.3M | ﹤0.01% |
147,437
-29,411
| -17% | -$3.65M |
|
935
LKQ Corp
LKQ
$8.26B
| $18.2M | ﹤0.01% |
367,688
+1,788
| +0.5% | +$88.5K |
|
936
FormFactor
FORM
$2.27B
| $18.1M | ﹤0.01% |
518,239
-149,419
| -22% | -$5.22M |
|
937
iShares Core S&P 500 ETF
IVV
$670B
| $18.1M | ﹤0.01% |
42,106
-493
| -1% | -$212K |
|
938
A10 Networks
ATEN
$1.26B
| $18.1M | ﹤0.01% |
1,202,238
+18,627
| +2% | +$280K |
|
939
Snap-on
SNA
$16.9B
| $17.9M | ﹤0.01% |
70,317
-1,275
| -2% | -$325K |
|
940
Revvity
RVTY
$9.58B
| $17.9M | ﹤0.01% |
161,833
-3,812
| -2% | -$422K |
|
941
WEX
WEX
$5.81B
| $17.9M | ﹤0.01% |
95,173
-6,025
| -6% | -$1.13M |
|
942
Lamb Weston
LW
$7.79B
| $17.7M | ﹤0.01% |
191,006
+578
| +0.3% | +$53.4K |
|
943
Virtus Investment Partners
VRTS
$1.31B
| $17.5M | ﹤0.01% |
86,457
-237
| -0.3% | -$47.9K |
|
944
Masco
MAS
$15.3B
| $17.4M | ﹤0.01% |
325,726
-2,599
| -0.8% | -$139K |
|
945
ServisFirst Bancshares
SFBS
$4.6B
| $17.4M | ﹤0.01% |
333,191
+95,817
| +40% | +$5M |
|
946
Evolent Health
EVH
$1.07B
| $17.4M | ﹤0.01% |
637,878
-212,383
| -25% | -$5.78M |
|
947
Trex
TREX
$6.43B
| $17.4M | ﹤0.01% |
281,789
-304
| -0.1% | -$18.7K |
|
948
Palomar
PLMR
$3.18B
| $17.2M | ﹤0.01% |
338,233
-409,875
| -55% | -$20.8M |
|
949
Synchrony
SYF
$27.8B
| $17.1M | ﹤0.01% |
560,667
-25,608
| -4% | -$783K |
|
950
Amicus Therapeutics
FOLD
$2.45B
| $17M | ﹤0.01% |
1,397,095
+4,481
| +0.3% | +$54.5K |
|